Literature DB >> 19039646

Pylorus-preserving pancreaticoduodenectomy in patients undergoing chronic hemodialysis.

Hiroki Uchida1, Kohei Shibata, Seiichiro Kai, Kentaro Iwaki, Masayuki Ohta, Seigo Kitano.   

Abstract

This report describes three patients who underwent a pylorus-preserving pancreaticoduodenectomy (PpPD) and received maintenance hemodialysis due to chronic renal failure. The three cases were diagnosed to have bile duct cancer, intraductal papillary mucinous neoplasm, and carcinoma of the ampulla of Vater, respectively. They underwent chronic hemodialysis for 7.7 years. They all underwent a PpPD with lymph node dissection. The mean operation time was 373 min and mean blood loss was 647 ml. During the postoperative courses, hemodialysis was restarted on postoperative day 1 in all three cases. In the three patients, only minor complications were experienced and these were treated conservatively. The mean postoperative hospital stay was 48 days. Two patients are still alive 135 and 21 months after the operation, respectively, but the other patient died of another disease 21 months after the PpPD. A PpPD may therefore be safe and feasible even in patients receiving chronic hemodialysis.

Entities:  

Mesh:

Year:  2008        PMID: 19039646     DOI: 10.1007/s00595-008-3746-2

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  10 in total

1.  One thousand consecutive pancreaticoduodenectomies.

Authors:  John L Cameron; Taylor S Riall; JoAnn Coleman; Kenneth A Belcher
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

2.  TREATMENT OF CARCINOMA OF THE AMPULLA OF VATER.

Authors:  A O Whipple; W B Parsons; C R Mullins
Journal:  Ann Surg       Date:  1935-10       Impact factor: 12.969

3.  Liver resection for hepatocellular carcinoma in patients with end-stage renal failure.

Authors:  S B Cheng; C C Wu; K H Shu; W L Ho; J T Chen; D C Yeh; T J Liu; F K P'eng
Journal:  J Surg Oncol       Date:  2001-12       Impact factor: 3.454

4.  Possibility of hepatic resection in patients on maintenance hemodialysis.

Authors:  M Yamagata; T Kanematsu; T Matsumata; T Nishizaki; T Utsunomiya; K Sugimachi; S Okuda
Journal:  Hepatogastroenterology       Date:  1993-06

Review 5.  Gastroparesis after a pylorus-preserving pancreatoduodenectomy.

Authors:  Masao Tanaka
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

6.  No mortality among 100 consecutive pancreaticoduodenectomies in a middle-volume center.

Authors:  Yasuyuki Suzuki; Yasuhiro Fujino; Tetsuo Ajiki; Takashi Ueda; Tetsuya Sakai; Yasuki Tanioka; Yoshikazu Kuroda
Journal:  World J Surg       Date:  2005-11       Impact factor: 3.352

7.  Factors influencing morbidity and mortality after pancreaticoduodenectomy: critical analysis of 221 resections.

Authors:  T C Böttger; T Junginger
Journal:  World J Surg       Date:  1999-02       Impact factor: 3.352

8.  Mortality in dialysis patients: analysis of the causes of death.

Authors:  L U Mailloux; A G Bellucci; B M Wilkes; B Napolitano; R T Mossey; M Lesser; P A Bluestone
Journal:  Am J Kidney Dis       Date:  1991-09       Impact factor: 8.860

9.  Zero mortality after 152 consecutive pancreaticoduodenectomies with pancreaticogastrostomy.

Authors:  Gerard V Aranha; Pamela J Hodul; Steven Creech; William Jacobs
Journal:  J Am Coll Surg       Date:  2003-08       Impact factor: 6.113

10.  Risk factors for complications after pancreatic head resection.

Authors:  Ulrich Adam; Frank Makowiec; Hartwig Riediger; Wolfgang D Schareck; Stefan Benz; Ulrich T Hopt
Journal:  Am J Surg       Date:  2004-02       Impact factor: 2.565

  10 in total
  2 in total

1.  Critical appraisal of the International Study Group of Pancreatic Surgery (ISGPS) consensus definition of postoperative hemorrhage after pancreatoduodenectomy.

Authors:  Thilo Welsch; Hanna Eisele; Stefanie Zschäbitz; Ulf Hinz; Markus W Büchler; Moritz N Wente
Journal:  Langenbecks Arch Surg       Date:  2011-05-25       Impact factor: 3.445

2.  Hepatic and pancreatic resection in patients with end-stage renal disease: a propensity analysis.

Authors:  Andrew S Barbas; Paul J Speicher; Bryan M Clary
Journal:  HPB (Oxford)       Date:  2014-06-16       Impact factor: 3.647

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.